Amgen "market perform"

31.07.07 - Rodman & Renshaw

NEW YORK, July 31 (newratings.com) - Analyst Michael G King of Rodman & Renshaw reiterates his "market perform" rating on Amgen Inc (AMGN).

In a research note published this morning, the analyst mentions that The Centers for Medicare & Medicaid Services (CMS) has announced its final national coverage determination (NCD) for the usage of Erythropoiesis Stimulating Agpents (ESAs) in cancer as well as related neoplastic conditions. CMS has modified its initial coverage decision, which is favourable for Johnson & Johnson and Amgen, the analyst adds.